Avantor (NYSE:AVTR) Price Target Lowered to $31.00 at Royal Bank of Canada

Avantor (NYSE:AVTR) had its target price cut by Royal Bank of Canada from $33.00 to $31.00 in a research report sent to investors on Monday,Benzinga reports. They currently have an outperform rating on the stock.

A number of other brokerages have also recently weighed in on AVTR. Raymond James reduced their price target on shares of Avantor from $29.00 to $26.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 21st. Barclays lowered their price target on Avantor from $26.00 to $23.00 and set an “overweight” rating for the company in a report on Monday. Robert W. Baird reduced their price objective on Avantor from $27.00 to $26.00 and set an “outperform” rating on the stock in a research note on Monday, October 28th. Stifel Nicolaus lowered their target price on Avantor from $28.00 to $26.00 and set a “buy” rating for the company in a research note on Monday. Finally, Wells Fargo & Company reduced their price target on Avantor from $28.00 to $25.00 and set an “overweight” rating on the stock in a research report on Monday. Three investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.com, Avantor has a consensus rating of “Moderate Buy” and an average price target of $26.15.

Avantor Stock Down 0.9 %

Shares of AVTR opened at $19.00 on Monday. Avantor has a fifty-two week low of $18.49 and a fifty-two week high of $28.00. The company’s fifty day moving average is $21.73 and its two-hundred day moving average is $23.47. The firm has a market cap of $12.93 billion, a PE ratio of 41.30, a price-to-earnings-growth ratio of 3.87 and a beta of 1.28. The company has a quick ratio of 1.06, a current ratio of 1.54 and a debt-to-equity ratio of 0.84.

Avantor (NYSE:AVTR) last issued its earnings results on Wednesday, February 12th. The company reported $0.27 earnings per share for the quarter, beating analysts’ consensus estimates of $0.26 by $0.01. Avantor had a return on equity of 12.24% and a net margin of 4.54%. During the same period in the previous year, the company earned $0.22 EPS. Analysts forecast that Avantor will post 0.98 earnings per share for the current year.

Institutional Trading of Avantor

A number of hedge funds have recently made changes to their positions in the stock. State Street Corp raised its stake in Avantor by 58.0% during the third quarter. State Street Corp now owns 22,368,244 shares of the company’s stock valued at $578,666,000 after buying an additional 8,206,695 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of Avantor by 653.0% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 6,174,736 shares of the company’s stock valued at $159,740,000 after acquiring an additional 5,354,678 shares during the last quarter. FMR LLC increased its holdings in shares of Avantor by 557.2% in the 3rd quarter. FMR LLC now owns 4,675,283 shares of the company’s stock valued at $120,950,000 after acquiring an additional 3,963,912 shares during the last quarter. Janus Henderson Group PLC raised its position in shares of Avantor by 18.2% during the 3rd quarter. Janus Henderson Group PLC now owns 17,692,705 shares of the company’s stock valued at $457,710,000 after acquiring an additional 2,719,615 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new position in Avantor during the fourth quarter worth $33,091,000. Institutional investors and hedge funds own 95.08% of the company’s stock.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.